Cipla Limited — Ipratropium Exporter Profile
Indian Pharmaceutical Exporter · #1 for Ipratropium · $20.1M export value · DGFT Verified
Cipla Limited is the #1 Indian exporter of Ipratropium with $20.1M in export value and 402 verified shipments. Cipla Limited holds a 35.2% market share in Ipratropium exports across 19 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Ipratropium Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Ipratropium?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $4.2M | 217 | 50.8% |
| SOUTH AFRICA | $1.4M | 41 | 16.8% |
| NEW ZEALAND | $522.5K | 30 | 6.3% |
| BELGIUM | $358.1K | 39 | 4.3% |
| SRI LANKA | $325.7K | 21 | 3.9% |
| MALAYSIA | $263.7K | 6 | 3.2% |
| LEBANON | $192.7K | 10 | 2.3% |
| PHILIPPINES | $180.4K | 4 | 2.2% |
| MEXICO | $144.6K | 9 | 1.7% |
| FINLAND | $119.3K | 3 | 1.4% |
Cipla Limited exports Ipratropium to 19 countries. The largest destination is UNITED STATES accounting for 50.8% of Cipla Limited's Ipratropium shipments, followed by SOUTH AFRICA (16.8%) and NEW ZEALAND (6.3%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Ipratropium from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CIPLA USA INC UPS SUPPLY CHAIN SOLU | UNITED STATES | $4.0M | 204 |
| MEDPRO PHARMACEUTICA (PTY) LTD | SOUTH AFRICA | $953.7K | 30 |
| BREATHEFREE LANKA PVT LTD | SRI LANKA | $276.0K | 17 |
| CIPLA USA INC UPS SUPPLY CHAIN SOL | UNITED STATES | $258.0K | 13 |
| REX MEDICAL LTD, | NEW ZEALAND | $247.1K | 11 |
| REX MEDICAL LTD | NEW ZEALAND | $218.9K | 14 |
| CIPLA MALAYSIA SDN BHD | MALAYSIA | $213.7K | 5 |
| MEDPRO PHARMACEUTICA PTY LTD | SOUTH AFRICA | $171.8K | 5 |
| UNILAB INC | PHILIPPINES | $150.0K | 3 |
| MEDPRO PHARMACEUTICA (PTY) LTD, | SOUTH AFRICA | $150.0K | 3 |
Cipla Limited supplies Ipratropium to 42 buyers globally. The largest buyer is CIPLA USA INC UPS SUPPLY CHAIN SOLU (UNITED STATES), followed by MEDPRO PHARMACEUTICA (PTY) LTD (SOUTH AFRICA) and BREATHEFREE LANKA PVT LTD (SRI LANKA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Ipratropium Export Value and How Much Does Cipla Limited Contribute?
India exported $27.7M worth of Ipratropium through 2,297 shipments from 173 suppliers to 81 countries, serving 306 buyers globally. Cipla Limited contributes $20.1M to this total, accounting for 35.2% of India's Ipratropium exports. Cipla Limited ships Ipratropium to 19 countries through 42 buyers.
What Is the Average Shipment Value for Cipla Limited's Ipratropium Exports?
Cipla Limited's average Ipratropium shipment value is $50.0K per consignment, based on 402 shipments totaling $20.1M. The largest destination is UNITED STATES (50.8% of Cipla Limited's Ipratropium exports).
How Does Cipla Limited Compare to Other Indian Ipratropium Exporters?
Cipla Limited ranks #1 among 173 Indian Ipratropium exporters with a 35.2% market share. The top 3 exporters are CIPLA LIMITED ($20.1M), AHLCON PARENTERALS (INDIA) LIMITED ($2.5M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($2.3M). Cipla Limited processed 402 shipments to 19 destination countries.
What Ipratropium Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| IPRATROPIUM BROMIDE AND ALBUTEROL SULFAT | $1.8M | 50 |
| DUOLIN RESPULES 2.5ML (IPRATROPIUM BROMI | $853.7K | 28 |
| IPRATROPIUM BROMIDE AND ALBUTEROLSULFATE INHALATION SOLUTION 0.5MG &3MG/3ML; NDC NO. 6909717353; ANDA NO. :#0 | $194.5K | 10 |
| DUAVENT500MCG NEB 2.5ML(IPRATROPIUM BROM | $150.0K | 3 |
| IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE INHALATION SOLUTION 0.5MG & 3MG/3ML NDC NO. 6909717353 ANDA NO. 077559 6 | $138.4K | 5 |
| IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE INHALATION SOLUTION 0.5MG & 3MG/3ML NDC NO. 6909717364 ANDA NO. 077559 (12 | $122.3K | 3 |
| UNIVENT NASAL SPRAY (IPRATROPIUM BROMIDE NASAL SOLUTION 0.03%W/V (21MCG/MD)) (1X15 ML) | $100.0K | 2 |
| DUOLIN RESPULES (IPRATROPIUM BROMIDE 0.5 | $83.5K | 3 |
| IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE INHALATION SOLUTION 0.5MG & 3MG/3ML; NDC NO. 6909717353; ANDA NO. : | $82.8K | 7 |
| IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE INHALATION SOLUTION 0.5MG & 3MG/3ML; NDC NO. 6909717364; ANDA NO. : | $82.2K | 11 |
Cipla Limited exports 169 distinct Ipratropium formulations including tablets, capsules, syrups, and combination drugs. The top formulation is IPRATROPIUM BROMIDE AND ALBUTEROL SULFAT with 50 shipments worth $1.8M. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Ipratropium to Key Markets
What Cipla Limited must comply with to export Ipratropium to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
South Africa — SAHPRA
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cipla Limited Compare to Nearest Ipratropium Exporters?
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | CIPLA LIMITED ★ | $20.1M | 402 | 19 | $50.0K |
| 2 | AHLCON PARENTERALS (INDIA) LIMITED | $2.5M | 53 | 3 | $47.0K |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $2.3M | 153 | 1 | $14.8K |
Cipla Limited ranks #1 among 173 Indian Ipratropium exporters. Average shipment value of $50.0K compared to the market average of $160.3K. The closest competitors by value are AHLCON PARENTERALS (INDIA) LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED.
Which Indian Ports Ship Ipratropium Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 385 | 16.8% |
| SAHAR AIR CARGO ACC (INBOM4) | 306 | 13.3% |
| DELHI AIR | 232 | 10.1% |
| DELHI AIR CARGO ACC (INDEL4) | 216 | 9.4% |
| NHAVA SHEVA SEA (INNSA1) | 198 | 8.6% |
| JNPT | 86 | 3.7% |
| JNPT/ NHAVA SHEVA SEA | 83 | 3.6% |
| NHAVA SHEVA | 82 | 3.6% |
What Other Respiratory Products Does Cipla Limited Export?
Cipla Limited also exports these respiratory products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Cipla Limited's Ipratropium Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Ipratropium, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Ipratropium — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Ipratropium shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 402 individual customs records matching Cipla Limited exporting Ipratropium, covering 169 formulations to 19 countries via 42 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 81+ countries, 306+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Ipratropium Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Ipratropium exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Ipratropium Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Ipratropium. For current shipment-level data, contact TransData Nexus.